Skip to main content

Advertisement

SpringerLink
Log in

Loss of Bad expression confers poor prognosis in non-small cell lung cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Proapoptotic BH-3-only protein Bad (Bcl-Xl/Bcl-2-associated death promoter homolog, Bad) initiates apoptosis in human cells, and contributes to tumorigenesis and chemotherapy resistant in malignancies. This study explored association between the Bad expression level and prognosis in patients with non-small cell lung cancer (NSCLC). In our study, a cohort of 88 resected primary NSCLC cases were collected and analyzed. Bad expression level was determined via immunohistochemical staining assay. The prognostic significances of Bad expression were evaluated with univariate and multivariate survival analysis. The results showed that compared with normal lung tissues, Bad expression level significantly decreased in NSCLC (P < 0.05). Bad expression was associated with adjuvant therapy status. Loss of Bad independently predicted poor prognosis in whole NSCLC cohort and early stage subjects (T1 + T2 and N0 + N1) (all P < 0.05). Overall survival time was also drastically shortened for Bad negative phenotype in NSCLC patients with smoking history, especially lung squamous cell carcinoma (all P < 0.05). In conclusion, this study provided clinical evidence that loss of Bad is an independent and powerful predictor of adverse prognosis in NSCLC. Bad protein could be a new biomarker for selecting individual therapy strategies and predicting therapeutic response in subjects with NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.

    Article  PubMed  Google Scholar 

  2. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res. 2005;11(11):3974–86.

    Article  PubMed  CAS  Google Scholar 

  3. Han SW, Roman J. Targeting apoptotic signaling pathways in human lung cancer. Curr Cancer Drug Targets. 2010;10(6):566–74.

    Article  PubMed  CAS  Google Scholar 

  4. Kuroda J, Taniwaki M. Involvement of BH3-only proteins in hematologic malignancies. Crit Rev Oncol Hematol. 2009;71(2):89–101.

    Article  PubMed  Google Scholar 

  5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.

    Article  PubMed  CAS  Google Scholar 

  6. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer. 2005;5(3):231–7.

    Article  PubMed  CAS  Google Scholar 

  7. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647–56.

    Article  PubMed  CAS  Google Scholar 

  8. Maiti D, Bhattacharyya A, Basu J. Lipoarabinomannan from Mycobacterium tuberculosis promotes macrophage survival by phosphorylating Bad through a phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem. 2001;276(1):329–33.

    Article  PubMed  CAS  Google Scholar 

  9. Downward J. How BAD phosphorylation is good for survival. Nat Cell Biol. 1999;1(2):E33–5.

    Article  PubMed  CAS  Google Scholar 

  10. Datta SR, Katsov A, Hu L, Petros A, Fesik SW, Yaffe MB, et al. 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell. 2000;6(1):41–51.

    PubMed  CAS  Google Scholar 

  11. Gilmore AP, Valentijn AJ, Wang P, Ranger AM, Bundred N, O’Hare MJ, et al. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem. 2002;277(31):27643–50.

    Article  PubMed  CAS  Google Scholar 

  12. Ranger AM, Zha J, Harada H, Datta SR, Danial NN, Gilmore AP, et al. Bad-deficient mice develop diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003;100(16):9324–9.

    Article  PubMed  Google Scholar 

  13. Sinicrope FA, Rego RL, Foster NR, Thibodeau SN, Alberts SR, Windschitl HE, et al. Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers. Clin Cancer Res. 2008;14(13):4128–33.

    Article  PubMed  CAS  Google Scholar 

  14. Seow HF, Yip WK, Loh HW, Ithnin H, Por P, Rohaizak M. Immunohistochemical detection of phospho-Akt, phospho-BAD, HER2 and oestrogen receptors alpha and beta in Malaysian breast cancer patients. Pathol Oncol Res. 2011;16(2):239–48.

    Article  Google Scholar 

  15. Liu D, Huang Y, Chen B, Zeng J, Guo N, Zhang S, et al. Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma. Cancer. 2011;117(16):3763–73.

    Article  PubMed  CAS  Google Scholar 

  16. Travis WD, Brambilla E, Muller-Hermlink HK, Harris CC. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC; 2004.

    Google Scholar 

  17. UICC IUAC. TNM classification of malignant tumours, 6th ed. New York: Wiley; 2002.

    Google Scholar 

  18. NCCN. NCCN Clinical practice guideline in oncology-non-small cell lung cancer guideline 2004. http://www.nccn.org (2004).

  19. Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer. 2006;51(2):181–91.

    Article  PubMed  Google Scholar 

  20. Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ, Hewitt SM, et al. Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res. 2010;16(1):240–8.

    Article  PubMed  CAS  Google Scholar 

  21. Yu B, Sun X, Shen HY, Gao F, Fan YM, Sun ZJ. Expression of the apoptosis-related genes BCL-2 and BAD in human breast carcinoma and their associated relationship with chemosensitivity. J Exp Clin Cancer Res. 2011;29:107.

    Article  CAS  Google Scholar 

  22. Al-Bazz YO, Underwood JC, Brown BL, Dobson PR. Prognostic significance of Akt, phospho-Akt and BAD expression in primary breast cancer. Eur J Cancer. 2009;45(4):694–704.

    Article  PubMed  CAS  Google Scholar 

  23. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC, et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA. 2006;103(40):14907–12.

    Article  PubMed  CAS  Google Scholar 

  24. Lee KW, Kim SG, Kim HP, Kwon E, You J, Choi HJ, et al. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res. 2008;68(6):1916–26.

    Article  PubMed  CAS  Google Scholar 

  25. Cannings E, Kirkegaard T, Tovey SM, Dunne B, Cooke TG, Bartlett JM. Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Res Treat. 2007;102(2):173–9.

    Article  PubMed  CAS  Google Scholar 

  26. Smith L, Berrieman HK, O’Kane SL, Campbell A, Maraveyas A, Cawkwell L. Immunohistochemical detection of apoptotic markers in gastric cancer. Oncol Res. 2006;15(9):441–4.

    PubMed  Google Scholar 

  27. Jin Z, Gao F, Flagg T, Deng X. Nicotine induces multi-site phosphorylation of Bad in association with suppression of apoptosis. J Biol Chem. 2004;279(22):23837–44.

    Article  PubMed  CAS  Google Scholar 

  28. Jin Z, Xin M, Deng X. Survival function of protein kinase C{iota} as a novel nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-activated bad kinase. J Biol Chem. 2005;280(16):16045–52.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

We are grateful to the patients and their families for participating in the study with cooperation and technicians in the Department of Pathology, West China Hospital, Sichuan University, who assisted us in collecting the tissue samples. This work was supported by grants from the National Basic Research Program of China (2009CB941200) and the Nature Science Foundation of China (grant 30771228 to H.X. and grant 30771227 to X.M.).

Conflict of interest

The authors declare that they have no conflicts of interest.

Author information

Authors and Affiliations

  1. Laboratory of Genetic Disease and Perinatal Medicine, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of China

    Yi Huang

  2. Department of Respiratory Medicine, West China Hospital, Sichuan University, 610041, Chengdu, People’s Republic of China

    Dan Liu, Bojiang Chen, Jing Zeng & Weimin Li

  3. Department of Integrated Traditional Chinese and West Medicine, West China Hospital, Sichuan University, Chengdu, P.R China

    Lei Wang

  4. Department of Pathology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China

    Shangfu Zhang

  5. Laboratory Stem Cell Biology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, 610041, Chengdu, People’s Republic of China

    Xianming Mo

Authors
  1. Yi Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bojiang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jing Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shangfu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xianming Mo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Weimin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xianming Mo or Weimin Li.

Additional information

Y. Huang and D. Liu contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, Y., Liu, D., Chen, B. et al. Loss of Bad expression confers poor prognosis in non-small cell lung cancer. Med Oncol 29, 1648–1655 (2012). https://doi.org/10.1007/s12032-011-0060-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-0060-4

Keywords

Search

Navigation